TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35591203

Group type: EXPERIMENTAL
Intervention: Balance and coordination training with vibrotactile sensory augmentation (SA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Balance and coordination training without vibrotactile sensory augmentation (SA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Balance and coordination training (both with and without SA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Training with vibrotactile SA vs. without SA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Training (both with and without SA)
Number of subjects: 10
Study: 616817652

Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation robot training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Body weight support treadmill training (BWSTT)
Number of subjects: 60
Study: 35642571

Group type: EXPERIMENTAL
Intervention: Nomogram model including age, marriage, grade, surgery, and tumor size
Number of subjects: 423
Study: 33674242

Group type: EXPERIMENTAL
Intervention: Maternal voice intervention (recorded maternal voice before, during, and after venipuncture)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 116
Study: 35190584

Group type: EXPERIMENTAL
Intervention: Positive attitude towards physical activity (PA)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Other predictors (not specified)
Number of subjects: 68
Study: 34493431

Group type: EXPERIMENTAL
Intervention: TAS-115 200 mg/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TAS-115 300 mg/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TAS-115 400 mg/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TAS-115 600 mg/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 36394838

Group type: EXPERIMENTAL
Intervention: DCVax-L plus SOC temozolomide
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: DCVax-L
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: DCVax-L in patients with methylated MGMT
Number of subjects: 331
Study: 34430972

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day
Number of subjects: 1330
Study: 32938935

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF, 8 h day−1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Extended feeding (EXF, 15 h day−1)
Number of subjects: 11
Study: 35998487

Group type: EXPERIMENTAL
Intervention: Questionnaire version with happiness question before categorical question
Number of subjects: 0

Group type: COMPARATOR
Intervention: Questionnaire version with happiness question after categorical question
Number of subjects: 0
Study: 33965626

Group type: EXPERIMENTAL
Intervention: Double dose of antenatal corticosteroids (ACS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of antenatal corticosteroids (ACS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32852426

Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid (PLLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bacteriostatic water (placebo)
Number of subjects: 20
Study: 34672833

Group type: EXPERIMENTAL
Intervention: Kinesio taping group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cold therapy group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 33007993

Group type: EXPERIMENTAL
Intervention: Robotics project activities including four robotics workshops and one extended pilot session.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 45
Study: 34347093

Group type: EXPERIMENTAL
Intervention: TransCon PTH 15, 18, or 21 µg PTH(1‐34)/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 33992298

Group type: EXPERIMENTAL
Intervention: Medium-density foam roller
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hard-density foam roller
Number of subjects: 10

Group type: COMPARATOR
Intervention: Contralateral leg (control)
Number of subjects: 10
Study: 36345115

Group type: EXPERIMENTAL
Intervention: IPR + EER group
Number of subjects: 81

Group type: COMPARATOR
Intervention: IPR group
Number of subjects: 81
Study: 32880992

Group type: EXPERIMENTAL
Intervention: NPEV positive by RT‐PCR
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: NPEV group
Number of subjects: 2519

Group type: COMPARATOR
Intervention: Clinical and laboratory findings
Number of subjects: 2519

Group type: COMPARATOR
Intervention: Adult patients
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: NPEV positive samples
Number of subjects: 2519
Study: 36215414

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 μg/kg ideal bodyweight
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 33350678

Group type: EXPERIMENTAL
Intervention: Second-line therapy (37% of patients received this treatment)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Single-agent second-line therapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no second-line therapy)
Number of subjects: 136
Study: 32466446

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (MCEP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 33594819

Group type: EXPERIMENTAL
Intervention: Adipose-derived regenerative cells (ADRCs) and lipotransfer to the axillary region
Number of subjects: 10
Study: 32069353

Group type: EXPERIMENTAL
Intervention: pGCD59 ELISA
Number of subjects: 693
Study: 33910604

Group type: EXPERIMENTAL
Intervention: IOERT
Number of subjects: 0

Group type: COMPARATOR
Intervention: External beam electrons
Number of subjects: 0
Study: 35484607

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg twice daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dapagliflozin-exenatide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 32145088

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy
Number of subjects: 24
Study: 33810451

Group type: EXPERIMENTAL
Intervention: >Your< Iron Syrup
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 32826114

Group type: EXPERIMENTAL
Intervention: CRS ± HIPEC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preemptive use of fresh frozen plasma
Number of subjects: 0
Study: 35426830

Group type: EXPERIMENTAL
Intervention: Bevacizumab 2.5 mg/kg administered as a one-time targeted intra-arterial infusion after blood-brain barrier disruption (BBBD)
Number of subjects: 10
Study: 32696185

Group type: EXPERIMENTAL
Intervention: Pelvic model-based simulation session
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lecture on SSLF procedure and anatomy
Number of subjects: 28
Study: 32559474

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg per day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 34473652

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) in addition to standard of care (SOC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 350
Study: 32517482

Group type: EXPERIMENTAL
Intervention: IABP insertion before PCI
Number of subjects: 275

Group type: COMPARATOR
Intervention: IABP insertion after PCI
Number of subjects: 275
Study: 35264106

Group type: EXPERIMENTAL
Intervention: Distal radial artery (dRA) catheterization
Number of subjects: 161

Group type: COMPARATOR
Intervention: Forearm radial artery (RA) catheterization
Number of subjects: 161
Study: 33315247

Group type: EXPERIMENTAL
Intervention: Mental contrasting with implementation intentions (MCII)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Stress management training
Number of subjects: 58
Study: 35710491

Group type: EXPERIMENTAL
Intervention: Reducing Stigma among Healthcare Providers (RESHAPE) training with facilitation by people with lived experience of mental illness (PWLE) and caregivers using PhotoVoice.
Number of subjects: 216

Group type: COMPARATOR
Intervention: Implementation-as-usual training on the World Health Organization Mental Health Gap Action Program Intervention Guide (mhGAP-IG) conducted by mental health specialists.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both arms (RESHAPE and implementation-as-usual) will evaluate reach as the accuracy of detection of mental illness in primary care facilities determined by psychiatrists at 3 months after PCPs diagnose the patients.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness and other RE-AIM outcomes will be assessed in both arms.
Number of subjects: 216
Study: 32688045

Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition (CON)
Number of subjects: 89
Study: 35411147

Group type: EXPERIMENTAL
Intervention: Intravenous glutamine (0.5 g/kg of 20% glutamine solution diluted with 0.9% NaCl up to 500 mL over 24 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (0.9% NaCl over 24 hours)
Number of subjects: 60
Study: 34622183

Group type: EXPERIMENTAL
Intervention: Inroads program (psychologist-supported, web-based cognitive behavioral therapy)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Inroads program
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (assessment plus alcohol information)
Number of subjects: 123
Study: 32627438

Group type: EXPERIMENTAL
Intervention: rTMS (110% motor threshold, 10 Hz, 20 minutes, three times a week for 4 weeks)
Number of subjects: 14
Study: 34406354

Group type: EXPERIMENTAL
Intervention: Exercise (aerobic exercise 3 times per week at 70% to 85% heart rate reserve for 12 weeks)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Escitalopram (up to 20 mg per day for 12 weeks)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Exercise and Escitalopram
Number of subjects: 128

Group type: COMPARATOR
Intervention: Exercise, Escitalopram, and Placebo
Number of subjects: 128
Study: 33206776

Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional Syringe Irrigation (CSI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProDesign Logic 25.06
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProDesign R 25.06
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProDesign Logic 35.05 with CSI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProDesign R 35.05 with CSI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProDesign Logic 35.05 with PUI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProDesign R 35.05 with PUI
Number of subjects: 80
Study: 36289464

Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 219
Study: 33493211

Group type: EXPERIMENTAL
Intervention: Albendazole, Mebendazole, and Praziquantel
Number of subjects: 88
Study: 33251823

Group type: EXPERIMENTAL
Intervention: ACT self-help book plus phone coaching (GSH-P; n=17)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ACT self-help book plus email prompts only (GSH-E; n=20)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waitlist condition (n=18)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: GSH-P
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: GSH-E
Number of subjects: 55
Study: 34047916

Group type: EXPERIMENTAL
Intervention: Combination of metformin (500 mg), pioglitazone (15 mg), and acetyl-L-carnitine (1500 mg), twice daily for 12 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Metformin (500 mg) plus pioglitazone (15 mg) and placebo (citric acid plus calcium carbonate), twice daily for 12 weeks
Number of subjects: 147
Study: 36088373

Group type: EXPERIMENTAL
Intervention: Crisis-focused Cognitive Behavioural Therapy for psychosis (CBTp)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 33387179

Group type: EXPERIMENTAL
Intervention: Supportive organizational climate with greater readiness for change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34389701

Group type: EXPERIMENTAL
Intervention: D-fortified yogurt drink (DY; containing 1000 IU vitamin D and 300 mg calcium)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ca+D-fortified yogurt drink (CDY; containing 1000 IU vitamin D and 500 mg calcium)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Plain yogurt drink (PY; containing no detectable vitamin D and 300 mg calcium)
Number of subjects: 75
Study: 35772625

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions
Number of subjects: 2717
Study: 34086190

Group type: EXPERIMENTAL
Intervention: Vericiguat plus standard of care
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 454
Study: 32107818

Group type: EXPERIMENTAL
Intervention: New supraventricular tachycardia (SVT)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: New-onset SVT
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Intermediate SVT-burden
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: High SVT-burden
Number of subjects: 325
Study: 36157393

Group type: EXPERIMENTAL
Intervention: Crossover backstroke-to-breaststroke turn
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Erector spinae and gastrocnemius medialis
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lower limb muscles during push-off activity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rotation efficacy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Different turning techniques
Number of subjects: 8
Study: 34048641

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 33685874

Group type: EXPERIMENTAL
Intervention: Intervention group (patient-centered interdisciplinary multifaceted intervention)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 284
Study: 33222937

Group type: EXPERIMENTAL
Intervention: Panic disorder patients with skin disease
Number of subjects: 246

Group type: COMPARATOR
Intervention: Panic disorder patients without skin disease (control group)
Number of subjects: 246
Study: 36342851

Group type: EXPERIMENTAL
Intervention: Soothing images
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Soothing sounds
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Combined images and sounds
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study: 33590772

Group type: EXPERIMENTAL
Intervention: ramucirumab-paclitaxel
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: ramucirumab
Number of subjects: 317
Study: 35451061

Group type: EXPERIMENTAL
Intervention: CelA2-M3 (H288F/H524Q) variant
Number of subjects: 36000000

Group type: COMPARATOR
Intervention: Parent CelA2-H288F
Number of subjects: 36000000

Group type: COMPARATOR
Intervention: Wildtype CelA2
Number of subjects: 36000000
Study: 34086518

Group type: EXPERIMENTAL
Intervention: Endurance training (EN1, N=10)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Concurrent training (CON, N=13)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Endurance training (EN2, N=12)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Endurance training (EN1) vs Concurrent training (CON)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Endurance training (EN2)
Number of subjects: 35
Study: 616082448

Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation (TES)
Number of subjects: 12
Study: 33219876

Group type: EXPERIMENTAL
Intervention: R25B instruments
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: R25 and R25B used in UltraAC
Number of subjects: 40

Group type: COMPARATOR
Intervention: R25 and R25B without simulated clinical use
Number of subjects: 40
Study: 35796290

Group type: EXPERIMENTAL
Intervention: Lactuca Sativa syrup (3 times a day for 72 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo syrup (3 times a day for 72 hours)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lactuca Sativa syrup
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 26
Study: 33399939

Group type: EXPERIMENTAL
Intervention: Single-use flexible ureteroscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 0
Study: 34910367

Group type: EXPERIMENTAL
Intervention: 1% VC-IP cream
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 2% VC-IP cream
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 3% VC-IP cream
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 69
Study: 33413038

Group type: EXPERIMENTAL
Intervention: Dyadic reading of books on emotion comprehension for five sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group reading classroom books
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dyadic reading of books on emotion comprehension
Number of subjects: 0
Study: 32884020

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg per day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both AAA and PAD
Number of subjects: 140
Study: 35987634

Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Bladder sparing operation
Number of subjects: 109
Study: 34701458

Group type: EXPERIMENTAL
Intervention: GC4711 100 mg IV infusion prior to each SBRT (5×10Gy)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo IV infusion prior to each SBRT (5×10Gy)
Number of subjects: 160
Study: 35857305

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 1050
Study: 34528277

Group type: EXPERIMENTAL
Intervention: IV administration of dexmedetomidine (loading dose 1.75 mcg/kg bwt followed by 1.75 mcg/kg bwt/h) with concurrent target sevoflurane dose reduction of 50%.
Number of subjects: 13

Group type: COMPARATOR
Intervention: No further treatment (group LPS; seven horses).
Number of subjects: 13
Study: 32924561

Group type: EXPERIMENTAL
Intervention: Homemade salivary substitute prepared using chamomile flower and flax seed
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chamomile flower and flax seed
Number of subjects: 40
Study: 33318079

Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy plus atezolizumab followed by maintenance niraparib plus atezolizumab
Number of subjects: 414

Group type: COMPARATOR
Intervention: Platinum based chemotherapy plus placebo of atezolizumab followed by maintenance niraparib plus placebo of atezolizumab
Number of subjects: 414
Study: 32507421

Group type: EXPERIMENTAL
Intervention: Plantago major syrup
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 46
Study: 33993394

Group type: EXPERIMENTAL
Intervention: Home management with auto-titrating CPAP (APAP) therapy and telemonitoring
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard care with diagnostic polysomnography (PSG) and in-lab APAP initiation
Number of subjects: 224
Study: 32960272

Group type: COMPARATOR
Intervention: Efavirenz/emtricitabine/tenofovir disoproxil fumarate (TDF)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Dolutegravir/emtricitabine/TDF
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Both interventions (Efavirenz and Dolutegravir)
Number of subjects: 510
Study: 32171278

Group type: EXPERIMENTAL
Intervention: Assertive outreach treatment (AOT) plus care as usual (CAU)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 160
Study: 36261145

Group type: EXPERIMENTAL
Intervention: nCPAP treatment with nasal mask or prongs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: nCPAP treatment
Number of subjects: 50
Study: 32854150

Group type: EXPERIMENTAL
Intervention: 1 g/kg/d S‐ILE for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2 g/kg/d S‐ILE for 6 weeks
Number of subjects: 40
Study: 33253259

Group type: EXPERIMENTAL
Intervention: tDNA-MI (structured low-calorie meal plan, diabetes-specific meal replacements, exercise prescription, and motivational interviewing)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: tDNA-CC (structured low-calorie meal plan, diabetes-specific meal replacements, exercise prescription, and conventional counseling)
Number of subjects: 230

Group type: COMPARATOR
Intervention: UC (usual care with standard dietary and exercise advice using conventional counseling)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: tDNA-MI
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: tDNA-CC
Number of subjects: 230

Group type: COMPARATOR
Intervention: UC
Number of subjects: 230
Study: 33541218

Group type: EXPERIMENTAL
Intervention: IO access using Arrow EZ-IO Vascular Access System in the proximal humerus or proximal tibia for 48 h
Number of subjects: 121
Study: 32428959

Group type: EXPERIMENTAL
Intervention: Aftercare by a specialist trained in osteology
Number of subjects: 70

Group type: COMPARATOR
Intervention: Regular aftercare by general practitioners or orthopedic surgeons
Number of subjects: 70
Study: 35030530

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (35% fat, 22% MUFA, <50% carbohydrates)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Low-fat diet (28% fat, 12% MUFA, >55% carbohydrates)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1002
Study: 34618594

Group type: EXPERIMENTAL
Intervention: Monetary payments of 24 US dollars (200 Swedish kronor)
Number of subjects: 8286

Group type: COMPARATOR
Intervention: Behavioral nudges
Number of subjects: 8286
Study: 33208665

Group type: EXPERIMENTAL
Intervention: Hydrofiber dressing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Polyurethane foam dressing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Porcine xenograft dressing
Number of subjects: 17